Literature DB >> 2933963

Atriopeptin II lowers cardiac output in conscious sheep.

B A Breuhaus, H H Saneii, M A Brandt, J E Chimoskey.   

Abstract

Atrial natriuretic peptides cause natriuresis, kaliuresis, diuresis, and hypotension. They relax vascular smooth muscle in vitro, and they dilate renal vessels in vivo. Hence, we tested the hypothesis that they produce hypotension by lowering total peripheral resistance. The studies were performed in conscious chronically instrumented sheep standing quietly in their cages. Atriopeptin II (AP II) was infused into the right atrium for 30 min at 0.1 nmol X kg-1 X min-1. Atriopeptin II lowers arterial pressure (9%, P less than 0.05) by lowering cardiac output (18%, P less than 0.05), stroke volume (28%, P less than 0.05), and right atrial pressure (2.3 mmHg, P less than 0.05). Heart rate and total peripheral resistance increase (16 and 13%, respectively, P less than 0.05). Partial ganglionic blockade with trimethaphan camsylate during AP II infusion prevents the increases in heart rate and total peripheral resistance. The changes in right atrial pressure, stroke volume, and cardiac output persist, and arterial pressure falls further (27%, P less than 0.05). These hemodynamic data are consistent with direct AP II-induced relaxation of venous smooth muscle with reduction of venous return, right atrial pressure, stroke volume, cardiac output, and arterial pressure, followed by reflex activation of the sympathetic nervous system to increase heart rate and total peripheral resistance. Because partial ganglionic blockade alone and AP II alone cause similar reductions in right atrial pressure (2.1 and 2.3 mmHg, respectively) but AP II causes a greater fall in stroke volume (28 vs. 13%), it is possible that AP II also causes coronary vasoconstriction.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2933963     DOI: 10.1152/ajpregu.1985.249.6.R776

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  9 in total

1.  Systemic and regional vascular effects of atrial natriuretic peptide in a rat model of chronic heart failure.

Authors:  H Drexler; M Finkh; S Höing; M Toth; H Just; R E Lang
Journal:  Basic Res Cardiol       Date:  1987 Nov-Dec       Impact factor: 17.165

2.  Is atrial natriuretic peptide really a hormone?

Authors:  R J Linden; M F Knapp
Journal:  Br Heart J       Date:  1986-10

3.  The inotropic effect of atrial natriuretic factor in the anesthetized rabbit.

Authors:  A J Rankin; F V Swift
Journal:  Pflugers Arch       Date:  1990-12       Impact factor: 3.657

4.  Atrial natriuretic peptide attenuates the development of pulmonary hypertension in rats adapted to chronic hypoxia.

Authors:  H Jin; R H Yang; Y F Chen; R M Jackson; S Oparil
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

Review 5.  Atrial natriuretic peptide. An overview of clinical pharmacology and pharmacokinetics.

Authors:  A C Tan; F G Russel; T Thien; T J Benraad
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

6.  Atrial natriuretic factor in chronic obstructive lung disease with pulmonary hypertension. Physiological correlates and response to peptide infusion.

Authors:  S Adnot; P Andrivet; P E Chabrier; J Piquet; P Plas; P Braquet; F Roudot-Thoraval; C Brun-Buisson
Journal:  J Clin Invest       Date:  1989-03       Impact factor: 14.808

7.  Vascular responses to local atrial natriuretic peptide infusion in man.

Authors:  D J Webb; N Benjamin; M J Allen; J Brown; M O'Flynn; J R Cockcroft
Journal:  Br J Clin Pharmacol       Date:  1988-09       Impact factor: 4.335

Review 8.  The involvement of atriopeptins in blood pressure regulation.

Authors:  B R Cole
Journal:  Pediatr Nephrol       Date:  1987-01       Impact factor: 3.714

Review 9.  Atrial natriuretic factor: physiologic actions and implications in congestive heart failure.

Authors:  B S Edwards; R S Zimmerman; J C Burnett
Journal:  Cardiovasc Drugs Ther       Date:  1987       Impact factor: 3.727

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.